SG11202009498RA - Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations - Google Patents

Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations

Info

Publication number
SG11202009498RA
SG11202009498RA SG11202009498RA SG11202009498RA SG11202009498RA SG 11202009498R A SG11202009498R A SG 11202009498RA SG 11202009498R A SG11202009498R A SG 11202009498RA SG 11202009498R A SG11202009498R A SG 11202009498RA SG 11202009498R A SG11202009498R A SG 11202009498RA
Authority
SG
Singapore
Prior art keywords
mutations
compounds
cancer cells
activity against
tumor activity
Prior art date
Application number
SG11202009498RA
Other languages
English (en)
Inventor
Jacqulyne Robichaux
John Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202009498RA publication Critical patent/SG11202009498RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202009498RA 2018-03-27 2019-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations SG11202009498RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648629P 2018-03-27 2018-03-27
US201862688049P 2018-06-21 2018-06-21
PCT/US2019/024353 WO2019191279A2 (fr) 2018-03-27 2019-03-27 Composés ayant une activité antitumorale contre des cellules cancéreuses portant des mutations her2 exon 19

Publications (1)

Publication Number Publication Date
SG11202009498RA true SG11202009498RA (en) 2020-10-29

Family

ID=68060750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009498RA SG11202009498RA (en) 2018-03-27 2019-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations

Country Status (14)

Country Link
US (1) US20210361655A1 (fr)
EP (1) EP3773551B1 (fr)
JP (1) JP7386174B2 (fr)
KR (1) KR102899689B1 (fr)
CN (1) CN112088000A (fr)
AU (1) AU2019243738B2 (fr)
BR (1) BR112020019251A2 (fr)
CA (1) CA3094108A1 (fr)
IL (1) IL277373A (fr)
MX (1) MX2020010121A (fr)
PH (1) PH12020551495A1 (fr)
RU (1) RU2020134932A (fr)
SG (1) SG11202009498RA (fr)
WO (1) WO2019191279A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007554A (es) * 2018-12-21 2021-08-11 Univ Texas Terapia de combinacion para el tratamiento de cancer.
MX2021011948A (es) * 2019-03-29 2022-01-04 Univ Texas Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2.
EP3956035A4 (fr) * 2019-04-17 2023-01-25 Board of Regents, The University of Texas System Composés contre le cancer portant des mutations egfr résistantes aux inhibiteurs de la tyrosine kinase

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0665852A1 (fr) 1993-07-09 1995-08-09 Amgen Boulder Inc. Polypeptides ctla4 recombinants et procede de fabrication
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (fr) 1999-08-24 2007-02-21 Medarex, Inc. Anticorps contre l'antigene ctla-4 humain et utilisation
AU2003233451A1 (en) 2002-03-26 2003-10-13 Massachusetts Institute Of Technology Targets, methods, and reagents for diagnosis and treatment of schizophrenia
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
US20180057603A1 (en) * 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN107003300B (zh) * 2014-12-12 2020-02-07 凯尔科迪股份有限公司 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法
CN107250108B (zh) * 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
KR102771603B1 (ko) * 2016-11-17 2025-02-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
KR20190054826A (ko) * 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
MX2021007554A (es) * 2018-12-21 2021-08-11 Univ Texas Terapia de combinacion para el tratamiento de cancer.
WO2020136417A2 (fr) * 2018-12-27 2020-07-02 Pratik Sharma Sous-système de manoeuvre de véhicule aérien sans pilote

Also Published As

Publication number Publication date
AU2019243738B2 (en) 2024-05-30
JP7386174B2 (ja) 2023-11-24
CA3094108A1 (fr) 2019-10-03
US20210361655A1 (en) 2021-11-25
EP3773551A2 (fr) 2021-02-17
WO2019191279A3 (fr) 2019-11-07
PH12020551495A1 (en) 2021-09-01
KR20200136417A (ko) 2020-12-07
JP2021519306A (ja) 2021-08-10
KR102899689B1 (ko) 2025-12-12
AU2019243738A1 (en) 2020-10-08
WO2019191279A2 (fr) 2019-10-03
CN112088000A (zh) 2020-12-15
MX2020010121A (es) 2021-01-08
RU2020134932A (ru) 2022-04-27
EP3773551A4 (fr) 2022-03-23
BR112020019251A2 (pt) 2021-01-12
IL277373A (en) 2020-11-30
EP3773551B1 (fr) 2024-10-16

Similar Documents

Publication Publication Date Title
IL286742A (en) Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr
IL273782A (en) Compositions of cells and bacteria for the treatment of colon cancer and methods for evaluating prognosis for these patients
IL277373A (en) Compounds with antitumor activity against cancer cells with a mutation in exon 19 of HER2
SMT202400524T1 (it) Derivati della chinazolina come agenti antitumorali
PT3394094T (pt) Receptores de células t específicos para o complexo antigénio-hla-a*02 do tumor ny-eso-1
PL4010329T3 (pl) Związki deuterowane do stosowania w leczeniu raka
IL286576A (en) Compounds with antitumor activity against cancer cells containing exon 21 her2 insertions
GB201903546D0 (en) Cancer treatment
GB201814866D0 (en) PeptiCRAd cancer therapy
HUE068630T2 (hu) Mutáns PiggyBac transzpozáz
GB202110535D0 (en) Stabilized Crispr complexes
SG11202007414XA (en) Osimertinib for use in the treatment of non-small cell lung cancer
EP3773650A4 (fr) Traitement néoadjuvant du cancer
SG11202009088VA (en) Compound with anticancer activity
IL285466A (en) Cancer treatment
GB201800733D0 (en) Cancer
PL3857230T3 (pl) Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
GB201820362D0 (en) Computed tomography imaging
GB201918313D0 (en) Cells for treating cancer
GB201913957D0 (en) Cancer
GB201819920D0 (en) Cancer treatment
HK40130794A (zh) 用於治疗癌症的vs-6063与ch5126766的组合
GB201907150D0 (en) Cancer treatment 2
HK40043736A (en) Combination therapy for cancers with braf mutation
HK40078764A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer